Skip to main content

CV Sciences, Inc. (CVSI)

OTCMKTS: CVSI · Delayed Price · USD
0.2400 -0.0100 (-4.00%)
Sep 20, 2021 3:58 PM EDT - Market closed
Market Cap27.80M
Revenue (ttm)20.74M
Net Income (ttm)n/a
Shares Out110.11M
EPS (ttm)-0.19
PE Ration/a
Forward PE15.63
Dividendn/a
Ex-Dividend Daten/a
Volume462,109
Open0.2525
Previous Close0.2500
Day's Range0.2300 - 0.2573
52-Week Range0.2300 - 1.1200
Beta0.24
Analystsn/a
Price Target0.44 (+83.3%)
Est. Earnings Daten/a

About CVSI

CV Sciences, Inc. operates as a life science company in the United States. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD name in various market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and con...

IndustryPersonal Products
Employees91
Stock ExchangeOTCMKTS
Ticker SymbolCVSI
Full Company Profile

News

CV Sciences, Inc. (CVSI) Reports Q2 Loss, Tops Revenue Estimates

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0.00% and 0.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

CV Sciences, Inc. Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

1 month ago - GlobeNewsWire

CV Sciences, Inc. Receives NutraIngredients-USA 2021 Product of the Year: Immune Support Award

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

1 month ago - GlobeNewsWire

CBD Can Reduce Nicotine Withdrawal Symptoms, Says New Study Done By CV Sciences

This week, CV Sciences (OTCQB:CVSI) released the results of a preclinical study that suggests that CBD can reduce nicotine withdrawal symptoms in smokeless tobacco users. The study, conducted in collabo...

1 month ago - Benzinga

Cantor Updates Ratings On Several Cannabis And CBD Stocks - MedMen, Jushi, cbdMD, CV Sciences

Cantor Fitzgerald's Pablo Zuanic provided updated ratings and estimates on several stocks from the cannabis and CBD sector, those being – MedMen Enterprises (OTCQF: MMNFF), Jushi Holdings (OTCQB: JUSHF)...

Other symbols:YCBD
3 months ago - Benzinga

CV Sciences, Inc. Reports First Quarter 2021 Financial Results

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products,...

4 months ago - GlobeNewsWire

Will CV Sciences, Inc. (CVSI) Report Negative Q1 Earnings? What You Should Know

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

CV Sciences, Inc. to Announce First Quarter 2021 Results on May 13, 2021

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products,...

4 months ago - GlobeNewsWire

CV Sciences and Alkemist Labs Form Partnership to Support the National Institute of Standards and Technology's Cannab...

SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today an...

5 months ago - GlobeNewsWire

CV Sciences, Inc. (CVSI) Reports Q4 Loss, Lags Revenue Estimates

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -350.00% and -22.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

CV Sciences, Inc. Reports Fiscal Year-End 2020 Financial Results

SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) product...

6 months ago - GlobeNewsWire

A Preview Of CV Sciences's Earnings

CV Sciences (OTC:CVSI) will be releasing its next round of earnings this Thursday, March 18. For all of the relevant information, here is your guide for Thursday's Q4 earnings announcement.

6 months ago - Benzinga

Will CV Sciences, Inc. (CVSI) Report Negative Q4 Earnings? What You Should Know

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

4 Marijuana Penny Stocks Winning Under Democratic Leadership

While cannabis legalization may not be a slam-dunk, that hasn't stopped investors from sending marijuana penny stocks to higher highs. The post 4 Marijuana Penny Stocks Winning Under Democratic Leadersh...

Other symbols:ALEAFMRMD
8 months ago - InvestorPlace

CV Sciences, Inc. Receives Nutritional Outlook's 2020 Best of the Industry Award

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

9 months ago - GlobeNewsWire

CV Sciences Inc's (CVSI) CEO Joe Dowling on Q3 2020 Results - Earnings Call Transcript

CV Sciences Inc's (CVSI) CEO Joe Dowling on Q3 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

CV Sciences, Inc. (CVSI) Reports Q3 Loss, Lags Revenue Estimates

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

CV Sciences, Inc. Announces Launch of PlusCBD™ Pet Product Line

Full line of soothing hemp extracts formulated exclusively for dogs and cats Full line of soothing hemp extracts formulated exclusively for dogs and cats

10 months ago - GlobeNewsWire

Will CV Sciences, Inc. (CVSI) Report Negative Earnings Next Week? What You Should Know

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

CV Sciences, Inc. to Announce Third Quarter 2020 Results on November 5, 2020

SAN DIEGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

10 months ago - GlobeNewsWire

CV Sciences, Inc. Announces PlusCBD™ Brand Refresh and New Product Launches

PlusCBD™ refresh reflects the brand’s core mission to improve quality of life through nature and science PlusCBD™ refresh reflects the brand’s core mission to improve quality of life through nature and ...

11 months ago - GlobeNewsWire

CV Sciences, Inc. Announces Launch of CV™ Defense Daily Immune Support

CV™ Defense now available on CV Sciences website and launching on Amazon.com next week CV™ Defense now available on CV Sciences website and launching on Amazon.com next week

1 year ago - GlobeNewsWire

CV Sciences, Inc. Launches New Website Reflecting Core Values and Mission of Improving Quality of Life Through Nature...

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp-derived cannabidiol (CBD) products, is p...

1 year ago - GlobeNewsWire

CV Sciences, Inc. Experts Contribute to Journal of Dietary Supplements First Special Issue on Cannabinoids

SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp-derived cannabidiol (CBD) products, is pl...

1 year ago - GlobeNewsWire

CV Sciences' (CVSI) CEO Joseph Dowling on Q2 2020 Results - Earnings Call Transcript

CV Sciences' (CVSI) CEO Joseph Dowling on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha